Regencell stock slips in premarket after Friday’s 14% drop puts focus back on volatility
Regencell Bioscience shares fell 3.2% to $20.48 in premarket trading Monday, after dropping nearly 14% in the prior session. The company last issued news in October, reporting no product sales, ongoing losses, and a “going concern” warning in its annual filing. Regencell has not applied for regulatory approvals and depends on raising more capital to continue operating.
